

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Reagent: Bevirimat Dimeglumine

Catalog Number: 12199

Lot Number: 1024531/L0106965/031

Release Category: A

Provided: 30mg

Chemical Name: 3-O-(3',3' -dimethylsuccinyl) betulinic acid di-N-methyl-D-glucamine salt

Empirical C₃₆H₅₆O₆ 2(C₇H₁₇NO₅) **Formula:**

HPLC Purity: 98.4% (by HPLC)

Molecular Weight: 975.28

CAS Num: 823821-85-8

Solubility: Methanol >30mg/ml

Water insoluble

Mechanical HIV viral maturation inhibitor **Action:**

Recommended

Storage:

Room Temperature

Contributor: Myrexis, Inc.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 07/24/2018 Page 1 of 2

References:

Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C, Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed EO, Wild CT. PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing.Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13555-60.

Zhou J, Huang L, Hachey DL, Chen CH, Aiken C. Inhibition of HIV-1 maturation via drug association with the viral Gag protein in immature HIV-1 particles. J Biol Chem. 2005 Dec 23;280(51):42149-55.

Li F, Zoumplis D, Matallana C, Kilgore NR, Reddick M, Yunus AS, Adamson CS, Salzwedel K, Martin DE, Allaway GP, Freed EO, Wild CT.Determinants of activity of the HIV-1 maturation inhibitor PA-457.Virology. 2006 Dec 5-20;356(1-2):217-24.

Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J, Allaway GP, Martin DE.Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother. 2007 Oct;51(10):3574-81.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, NIAID, NIH: Bevirimat from Myrexis, Inc. (cat#12199)".

Last Updated July 24, 2018

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 07/24/2018 Page 2 of 2